Sorry, Internet Explorer and the old Edge Versions are not supported...
Please use an up-to-date Firefox, Chrome, Opera or the new Chromium based Edge to visit this website.

⚠️ You are using an old version of Edge. ⚠️

This browser can not support the full functionality of this website. For a better user experience we recommend to use the latest version of Edge or other up-to-date Browsers like Firefox, Chrome or Opera...

Marvl

MARVL is a game-changing genome analysis software for disease discovery and treatment.

Marvl

MARVL is a game-changing genome analysis software for disease discovery and treatment.

Genome sequencing, assembly and analytics is key to detecting genetic mutations, variations and rearrangement in a patient’s DNA – and thus understanding which changes cause genetic disorders.

In the past years, the technology to assemble genomes has made enormous progress; the assembling of the genome of the axolotl, for example, has transformed regeneration research.

MARVL plans to provide next generation genome analysis software for disease discovery and treatment using the best software currently available on the market and to take it to the next level in terms of speed and user friendliness.

Genome sequencing, assembly and analytics is key to detecting genetic mutations, variations and rearrangement in a patient’s DNA – and thus understanding which changes cause genetic disorders.

In the past years, the technology to assemble genomes has made enormous progress; the assembling of the genome of the axolotl, for example, has transformed regeneration research.

MARVL plans to provide next generation genome analysis software for disease discovery and treatment using the best software currently available on the market and to take it to the next level in terms of speed and user friendliness.

We believe the large-scale application of assembly coupled with big-data analytics will bring enormous advantages to the development of novel therapeutic concepts and biomarker discovery.

Siegfried Schloissnig, Product Owner of Marvl

We believe the large-scale application of assembly coupled with big-data analytics will bring enormous advantages to the development of novel therapeutic concepts and biomarker discovery.

Siegfried Schloissnig, Product Owner of Marvl

Currently being trialed within BI, this has enormous potential as a top assembler and analytics tool, which could be used in clinical research and patient care.

We are always developing, testing and learning. Look out for more updates!

Currently being trialed within BI, this has enormous potential as a top assembler and analytics tool, which could be used in clinical research and patient care.

We are always developing, testing and learning. Look out for more updates!

Inside BI X GmbH
© 2020 BI X GmbH All rights reserved
A Boehringer Ingelheim company | Binger Strasse 173, 55216 Ingelheim / Rhein, Germany